atlas and cdk4/6 inhibitor trials presented by dr. john smith ii, compass oncology
Published 11 years ago • 174 plays • Length 31:32Download video MP4
Download video MP3
Similar videos
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
3:57
cdk 4/6 inhibitor as first-line therapy for advanced breast cancer
-
5:47
monarche and pallas: a tale of two cdk4/6 inhibitors | george sledge jr
-
6:36
adjuvant cdk4/6 inhibition in early-stage hr-positive breast cancer | ruth o'regan
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer
-
8:28
cdk4/6 inhibition in breast cancer
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
1:46
dr. sledge on impact of cdk 4/6 agents in breast cancer
-
2:52
mechanisms of resistance to cdk4/6 inhibitors in triple negative breast cancer
-
5:32
biomarkers for cdk4/6 inhibitors
-
4:15
hr breast cancer: factors in selecting a cdk4/6 inhibitor
-
4:15
case 2: choosing a cdk4/6 inhibitor in er breast cancer
-
5:16
the clinical potential of cdk4/6 inhibitors
-
4:45
cdk4/6 inhibitors for hr metastatic breast cancer
-
4:52
future directions: cdk4/6 inhibitors in breast cancer
-
6:19
selecting agents in cdk4/6 inhibition for hr mbc